Liverpool eye £40m+ for Harvey Elliott as interest builds after U21 Championship heroics
Elliott scored five goals in six matches to help the Young Lions retain their crown, capping a summer that has significantly raised his stock across Europe.
Advertisement
Despite his limited role in Arne Slot's title-winning Premier League side last season — with just two starts in the league — the club still value him highly.
Liverpool believe Elliott's experience at the top level, combined with his recent international success, places him above recent benchmarks such as Jarell Quansah's expected £35 million move to Bayer Leverkusen.
As a result, the Reds have made it clear they would only consider selling the versatile forward for more than £40 million if a buy-back clause is included, or upwards of £50 million without one.
The club are aware that Elliott is seeking more regular minutes at elite level, potentially in the Champions League, and may be open to a move abroad if a suitable opportunity arises.
Advertisement
Interest in Elliott is said to be building, though it remains to be seen whether any club is willing to match Liverpool's valuation.
The decision to demand a buy-back clause in some scenarios suggests that Liverpool are not completely closing the door on Elliott's long-term future at Anfield.
His combination of technical quality, tactical intelligence and age makes him an attractive proposition in the current market, especially for clubs looking for creative depth in wide or midfield areas.
Meanwhile, Liverpool's focus on reshaping the squad continues. While high-profile arrivals such as Florian Wirtz, Milos Kerkez and Jeremie Frimpong have grabbed headlines, outgoings are just as crucial in maintaining balance.
Advertisement
Quansah is close to joining Bayer Leverkusen, and further departures could follow, with Elliott's fellow England youth international Tyler Morton also expected to leave.
Elliott's next move could depend on whether clubs are willing to meet Liverpool's terms — but after his summer exploits, his name will remain on the radar across Europe as the window progresses.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Kate Middleton's mom strategy at her kids' sporting events is very relatable for exhausted parents anywhere
As parents, we don't always have the time; but we make the time. Panthea Parker of 'The Real Housewives of London' comes in contact with the Princess of Wales from time to time, as her son's school often plays sports against Lambrook School (where all three Wales children attend), and she has shared that Princess Catherine (who much of the world still calls Kate Middleton), is always present whenever a sports or school activity is happening. 'I see her quite a few times because my son's school plays against her son's school,' she told Hello! Magazine. 'So they play rugby and football against each other so we're always at her school or my school.' The two women aren't very well acquainted, but Parker is aware that Middleton is a constant fixture supporting her kids. "So classy, so lovely, and she never misses any of her children's matches, so really amazing. And nor do I, otherwise how do I know that?" she said in the interview. The Princess of Wales is famously a very hands-on parent, always present at all her kids' activities and sporting events (as referenced by royal expert Ingrid Seward in The Sun in a previous story). There's no doubt the future Queen of England has a lot on her plate, but she always makes the time to be present for her kids, and that's something we can all appreciate and relate to (or aspire to!). Solve the daily Crossword
Yahoo
16 minutes ago
- Yahoo
Arsenal's ruthless Eze coup shows intent
Arsenal's dramatic move to steal Eberechi Eze away from arch-rivals Tottenham Hotspur is a ruthless statement of intent designed to show this is the season they plan to finally claim the biggest prizes. Spurs were ready to roll out the welcoming carpet for Crystal Palace's England forward on Wednesday, the deal virtually done with every indication the 27-year-old was set on the move. It then filtered out that Arsenal were assessing the seriousness of a knee injury to forward Kai Havertz, which could potentially put a dent in their attacking resources - a weakness that played a significant part in manager Mikel Arteta's side ending empty handed for the fifth year in succession last season. Instead of taking the cheaper option of exploring the loan market, as was first expected, Arsenal went for broke in spectacular style by setting up a £60m coup to take Eze to Emirates Stadium from right under the noses of Spurs. Eze's move to Arsenal, which is now fully expected to be successfully concluded, is not simply a devastating psychological blow aimed across north London at Spurs. It is a clear signal that they have no intention of falling short in their stated aim of mounting a serious Premier League title challenge, as well as making inroads deep into the Champions League once more after reaching the semi-final last season. It is strategy in stark contrast to the inertia that gripped Arsenal last season, when their failure to solve an obvious problem - namely sign a recognised striker - cost them dearly. Spurs thought they had Eze wrapped up, the possibility of a cash-plus-Richarlison deal discussed, but Arsenal moved with lightning speed once they were confronted by the possibility of Havertz facing a spell on the sidelines. Arsenal have been linked with Eze all summer, but it was thought their interest had cooled once Ethan Nwaneri agreed a new five-year contract, on top of signing Chelsea winger Noni Madueke in a £48.5m deal. Havertz's injury, and its potential consequences, reignited that interest to leave Spurs stunned. Arsenal move ahead of Spurs in race for £60m Eze Football Daily: Isak's social statement & who else is on the move? Arteta knows this is the season he must land a major prize, and to do this he has been heavily backed by Arsenal's hierarchy. As well as Madueke, the Gunners have concluded moves to sign Spain's outstanding midfield man Martin Zubimendi in a deal worth up to £60m and, at least 12 months too late, a recognised striker in Viktor Gyokeres, signed from Sporting Lisbon for £64m. In Eze, who had two years left on his Palace contract, Arsenal will get a versatile forward rich in natural talent who is a match-winner - as he proved when scoring the winner against Manchester City in the FA Cup final in May. This was a follow-up to the spectacular right-foot finish that set Palace on their way to a 3-0 win over Aston Villa at Wembley in the semi-final. Eze also scored the Eagles' opener when they beat Fulham 3-0 at Craven Cottage in the quarter-final. Eze has demonstrated he has the temperament and talent for the big occasion when inspiring Palace to the first major trophy in their history. Arsenal will hope he has plenty of those occasions ahead. He is a scorer and creator of goals, adding real threat to Arsenal's front line, with 14 goals in all competitions last season. Eze was a boyhood Arsenal fan and was part of the club's academy until he was 13. He may have been initially keen on a move to Spurs, but once the Gunners showed their hand was only one part of north London he was heading to. He has achieved his goals the hard way, spending time at Fulham, Reading and Millwall before signing for Queen's Park Rangers. He left Loftus Road for Palace in a £19.5m deal in August 2020. Spurs believe they did all they could to conclude a deal - apart from actually concluding it - but it is a hammer blow to chairman Daniel Levy and manager Thomas Frank, who also thought they had a deal for Morgan Gibbs-White in the bag only for him to sign a new contract at Nottingham Forest. Arsenal will revel in the local rivalry of snatching away a prime transfer target for Spurs, but the wider context demonstrates the Gunners are deadly serious about ending the wait for success that now stretches back to 2020. Eze has previously admitted to "crying for a week" when he was let go by Arsenal in 2011, but this gifted forward has now been given a golden opportunity to make up for lost time. Latest Arsenal news, analysis and fan views Ask about Arsenal - what do you want to know?
Yahoo
16 minutes ago
- Yahoo
Basilea Pharmaceutica Ltd (BPMUF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Global In-Market Sales Increase: Procemba sales increased by 24.8% for the 12-month period ending March 2025. Royalty Income Growth: 21.7% year-on-year increase in royalty income. Operating Result: Positive operating result of CHF 24 million for the first six months of 2025. Additional Funding: Secured $39 million in non-dilutive funding from BAA. Revenue: Total revenue of CHF 104 million, a 36% increase compared to the first half of 2024. Operating Expenses: CHF 55.7 million, mainly due to costs associated with the ongoing phase 3 program. Net Profit: CHF 15.8 million, compared to CHF 20.7 million in the first half of 2024. Net Cash Position: Positive net cash position of CHF 50.7 million as of June 30, 2025. Operating Cash Flow: Positive cash flow of CHF 23.1 million from operating activities. Debt Reduction: Reduced total debt by CHF 138.3 million from 2022 through June 30, 2025. Full Year 2025 Guidance: Total revenue expected to increase by about 8% to CHF 225 million. R&D Expenses: Projected to rise to CHF 105 million for 2025. Operating Profit Guidance: Expected operating profit of approximately CHF 50 million for 2025. Warning! GuruFocus has detected 5 Warning Signs with BPMUF. Is BPMUF fairly valued? Test your thesis with our free DCF calculator. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Basilea Pharmaceutica Ltd (BPMUF) reported a strong financial performance for the first half of 2025, with a positive operating result of CHF 24 million. The company's leading commercial product, Procemba, saw a 24.8% increase in global in-market sales, contributing to a 21.7% year-on-year increase in royalty income. Basilea secured an additional $39 million in non-dilutive funding from BAA to support the development of its antifungal candidates. The company successfully launched its antibiotic Zayra in the US through a partnership with Innoviva Specialty Therapeutics. Basilea expanded its portfolio by in-licensing ceftibutin deaborbactam, a phase 3 ready novel oral antibiotic for complicated urinary tract infections. Negative Points The net profit for the first half of 2025 decreased to CHF 15.8 million from CHF 20.7 million in the first half of 2024, due to a one-time income tax benefit in the previous year. The company anticipates a 17% reduction in product revenue to about CHF 48 million year-on-year due to a decrease in product supply to Pfizer. R&D expenses are projected to rise to CHF 105 million, driven by the in-licensing transaction and associated costs. The phase 3 program for the newly in-licensed antibiotic is expected to start in approximately 18 months, which may delay potential revenue contributions. Currency fluctuations, particularly the devaluation of the US dollar against the Swiss franc, impacted financial results. Q & A Highlights Q: Why is there an 18-month delay before starting the phase 3 trial for the newly in-licensed antibiotic? Does this relate to securing additional funding? A: David Veitch, CEO, clarified that the delay is not due to funding issues. The 18-month period is necessary for regulatory interactions with health authorities and operational setup. Marc Engelhardt, CMO, added that the studies require a large patient supply, which takes time to prepare. Q: How does the expanded access program for fosmanogepix impact regulatory approval, given the large number of patients involved? A: Marc Engelhardt, CMO, explained that the data from the expanded access program could serve as confirmatory evidence in an NDA filing, provided it meets FDA guidelines for completeness and context. Q: How does the new oral antibiotic fit into the treatment landscape for complicated UTIs, which is dominated by IV treatments? A: Marc Engelhardt, CMO, stated that the oral antibiotic will serve both as an initial empirical therapy and a step-down treatment from IV antibiotics, offering flexibility in hospital and outpatient settings. Q: Why is there expected softness in product revenues in the second half of the year? A: Adesh Kaul, CFO, explained that the fluctuation is due to product delivery schedules and initial supplies related to the US launch and other markets, rather than any underlying weakness. Q: What factors could accelerate enrollment in the fosmanogepix phase 3 program? A: Marc Engelhardt, CMO, mentioned that geographic analysis and increased sponsor engagement at underperforming sites could enhance enrollment rates. Q: Can you provide details on the sales and marketing infrastructure for Zevtera's US rollout? A: David Veitch, CEO, highlighted that Innoviva Specialty Therapeutics has extensive experience in launching antibiotics, with a comprehensive US coverage including sales, medical affairs, and access teams. Q: How does the oral antibiotic compare to GSK's oral carbapenem in clinical development for complicated UTIs? A: Marc Engelhardt, CMO, noted that while there are similarities in trial design, the new antibiotic offers advantages in spectrum and dosing frequency, potentially capturing significant market share. Q: How is Crescemba performing in the APAC region, and how will it mitigate the impact of the 2027 loss of exclusivity? A: Adesh Kaul, CFO, reported strong growth in APAC, particularly in Japan, where exclusivity extends beyond 2027, contributing to sustained revenue despite upcoming patent expirations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
